Answers are grounded in this paper and cite their sources.
The FDA approval of oncolytic herpes simplex-1 virus (oHSV) therapy underscores its therapeutic promise and safety as a cancer immunotherapy. Despite this promise, the current efficacy of oHSV is significantly limited to a small subset of patients largely due to the resistance in tumor and tumor microenvironment (TME).
No takes yet. Share an insight, caveat, or question.
Noh et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: